International Journal of Clinical Research

Objective To investigate the value of folic acid combined with Helicobacter pylori (Hp) eradication therapy in treating chronic atrophic gastritis. Methods 200 patients with chronic atrophic gastritis admitted to our hospital from June 2024 to June 2025 were selected as study subjects and randomly divided into a monotherapy group and a combination group, with 100 cases in each group. The monotherapy group received conventional Hp eradication therapy, while the combination group received folic acid in addition to the conventional therapy. The Hp eradication rate, improvement in clinical symptoms and gastric mucosal pathological lesions, and the incidence of adverse reactions were compared between the two groups. Results The combination group showed a significantly higher Hp eradication rate. Improvements in clinical symptoms and gastric mucosal pathological lesions were more significant in the combination group compared to the monotherapy group, and the differences were statistically significant (p < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (p > 0.05). Conclusion Folic acid combined with Hp eradication therapy can significantly increase the Hp eradication rate in patients with chronic atrophic gastritis, improve clinical symptoms and gastric mucosal precancerous lesions, and is safe. It holds value for clinical promotion and application.

Chronic atrophic gastritis; Folic acid; Helicobacter pylori eradication therapy; Combined effect